Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Express Confidence in ColgatePalmolives Future Performance

Elaine Mendonca by Elaine Mendonca
January 29, 2024
in Breaking News
0
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On January 29, 2024, Dara Mohsenian, an analyst at Morgan Stanley, expressed a positive outlook on Colgate-Palmolive (NYSE:CL) by maintaining an Overweight rating and increasing the price target from $85 to $93. This adjustment was made after careful consideration of the company’s performance and growth prospects. Similarly, Olivia Tong, an analyst at Raymond James, also upgraded Colgate-Palmolive to Outperform, setting a price target of $91. This decision was influenced by the strong Q4 earnings and a promising outlook for 2024. Both analysts’ adjustments demonstrate their confidence in the company’s future performance, taking into account various factors such as financial results, market conditions, and growth opportunities.

CL Stock Shows Strong Performance on January 29, 2024: Positive Momentum and Factors to Consider

On January 29, 2024, CL stock showcased a strong performance, with the price trading near the top of its 52-week range and above its 200-day simple moving average. This indicates a positive price momentum for the stock.

The price of CL shares experienced an increase of $0.91 since the market last closed, representing a rise of 1.10%.

Furthermore, CL stock opened at $83.15, which was $0.32 higher than its previous closing price.

The strong performance of CL stock on January 29, 2024, can be attributed to various factors. It is possible that the company has reported positive earnings or announced significant developments that have instilled confidence in investors. Additionally, favorable market conditions and overall positive sentiment towards the stock market could have contributed to the rise in CL stock price.

Investors and analysts will closely monitor the price movement of CL stock in the coming days to assess whether this positive momentum continues. If the stock manages to sustain its upward trajectory and remains above its 200-day simple moving average, it could indicate a bullish trend for CL and attract further investor interest.

However, it is important to note that stock performance is subject to various market factors and can be volatile. Therefore, investors should conduct thorough research and analysis before making any investment decisions.

Colgate-Palmolive (CL) Stock Shows Steady Performance in Q4 2023

Title: Colgate-Palmolive (CL) Stock Performance Holds Steady in Q4 2023

Introduction

On January 29, 2024, Colgate-Palmolive (CL) announced its financial performance for the fourth quarter of 2023. This article will analyze the stock performance of CL based on the provided data from CNN Money.

Revenue Stability

Colgate-Palmolive reported a total revenue of $19.46 billion for the past year, representing an 8.29% increase compared to the previous year. However, the revenue remained flat at $4.95 billion for the fourth quarter of 2023.

Net Income Growth

The company’s net income for the past year stood at $2.30 billion, reflecting a significant 28.85% increase compared to the previous year. Despite this impressive growth, the net income held flat at $718.00 million for the fourth quarter of 2023.

Earnings per Share Stability

Colgate-Palmolive’s earnings per share (EPS) also demonstrated positive growth. The EPS for the past year was reported at $2.77, indicating a notable 30.17% increase over the previous year. However, similar to the revenue and net income, the EPS remained flat at $0.87 for the fourth quarter of 2023.

Stock Performance Analysis

Colgate-Palmolive’s stock performance on January 29, 2024, can be evaluated based on its revenue, net income, and earnings per share. The stability in all three metrics since the previous quarter indicates that the market has reacted positively to the company’s financial results.

Conclusion

Colgate-Palmolive’s stock performance on January 29, 2024, demonstrates its resilience and ability to adapt to market conditions. Despite the challenging economic environment, the company’s revenue, net income, and earnings per share remained stable since the previous quarter. Investors may view this performance positively, as it suggests that the company has the potential to deliver consistent returns in the future.

Tags: CL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Automotive Stock Market Today

Rivian Automotive Experiences Trading Surge and Anticipation for R2 Model Launch

Beverages Industry Markets and money (1)

Bearish Options Activity Surrounding Celsius Holdings

Automotive Stock Market Today

GM Dealers Push for Expanded Hybrid Options as Alternative to Electric Vehicles

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com